These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
122 related items for PubMed ID: 16224383
1. New approaches to the treatment of thrombocytosis. Fruchtman S. Clin Adv Hematol Oncol; 2003 Feb; 1(2):92-3. PubMed ID: 16224383 [No Abstract] [Full Text] [Related]
2. [The use of anagrelide to treat thrombocytosis in connection with the chronic myeloproliferative disease]. Jantunen E, Penttilä K, Kuittinen T, Nousiainen T. Duodecim; 2006 Feb; 122(4):453-7. PubMed ID: 16623100 [No Abstract] [Full Text] [Related]
7. [What should follow a treatment for pruritus in thrombocytosis?]. Wollina U. Dtsch Med Wochenschr; 2003 Mar 21; 128(12):631. PubMed ID: 12649803 [No Abstract] [Full Text] [Related]
10. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients]. Burkhard R, Adam H, Widmer L, Honegger HP. Schweiz Med Wochenschr; 1998 Nov 14; 128(46):1808-12. PubMed ID: 9857387 [Abstract] [Full Text] [Related]
11. Thrombocytosis. Schafer AI. N Engl J Med; 2004 Mar 18; 350(12):1211-9. PubMed ID: 15028825 [No Abstract] [Full Text] [Related]
13. [Anagrelide--a new drug to reduce platelets in myeloproliferative diseases]. Bennett M. Harefuah; 1999 May 02; 136(9):717-20. PubMed ID: 10955097 [No Abstract] [Full Text] [Related]
15. Primary thrombocytosis and myocardial ischemic syndrome in a young woman. Adlakha A, Bechard DL, Geer MR. Am Heart J; 1992 Mar 02; 123(3):786-90. PubMed ID: 1539533 [No Abstract] [Full Text] [Related]
17. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR]. Penka M, Doubek M, Schwarz J, Pytlík R, Dulícek P, Kissová J, Hlusí A, Vozobulová V, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Schutzová M, Hadacová I, Hochová I, Voglová J, Siroký O, Belada D, Lhot'anová T, Bubeník B, Vránová M, Micaníková M, Dusek L. Vnitr Lek; 2006 May 02; 52(5):498-503. PubMed ID: 16771099 [Abstract] [Full Text] [Related]
18. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlögl E, Gisslinger H. Cancer; 2004 Nov 15; 101(10):2239-46. PubMed ID: 15476273 [Abstract] [Full Text] [Related]
19. Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review. Hong Y, Erusalimsky JD. Platelets; 2002 Nov 15; 13(7):381-6. PubMed ID: 12487784 [No Abstract] [Full Text] [Related]
20. Anagrelide: a new drug for treating thrombocytosis. Silverstein MN, Petitt RM, Solberg LA, Fleming JS, Knight RC, Schacter LP. N Engl J Med; 1988 May 19; 318(20):1292-4. PubMed ID: 3362187 [Abstract] [Full Text] [Related] Page: [Next] [New Search]